Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5797-5804

  El Helw, Abdel Rahim M ^a   Fahmy, Usama A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Factorial design; Hyperlipidemia; Nano vesicles; Statins

Indexed keywords

DRUG CARRIER; FLUINDOSTATIN; LIPID; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ELIMINATION HALF-LIFE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; RAT; SUSTAINED DRUG RELEASE; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; HALF LIFE TIME; MALE; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; SOLUBILITY; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; FATTY ACIDS, MONOUNSATURATED; HALF-LIFE; INDOLES; LIPIDS; MALE; NANOSTRUCTURES; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84941908852     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S91556     Document Type: Article

References (20)

1. Lopes-Virella MF, Virella GT: U.S. Patent and Trademark Office. Washington, DC. 2013; U.S. Patent No. 8,568, 995.
2. Yano M, Ikeda M, Abe K, et al. Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. Hepatology. 2009;50(3):678–688.
3. Kah J, Wüstenberg A, Keller AD, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012;28(3):1077–1083.
4. Lee CK, Choi JS, Bang JS. Effects of fluvastatin on the pharmacokinetics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by fluvastatin. Korean J Physiol Pharmacol. 2013;17(3):245–251.
5. Ekambaram P, Abdul Hasan Sathali A, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2(1):80–102.
6. Liu Z, Zhang X, Wu H, et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm. 2011;37(4):475–481.
7. Elshafeey A, Bendas E, Mohamed O. Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. AAPS Pharm Sci Tech. 2009;10(2):361–367.
8. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010;99:306–314.
9. Gonzalez O, Iriarte G, Rico E, et al. LC–MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2685–2692.
10. Koch S, Pohl P, Cobet U, Rainov NG. Ultrasound enhancement of liposome-mediated cell transfection is caused by cavitation effects. Ultrasound Med Biol. 2000;26(5):897–903.
11. Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi. 2008;128(2): 269–280.
12. Aburahma MH, Badr-Eldin SM. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin Drug Deliv. 2014;11(12):1865–1883.
13. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139–151.
14. Ballantyne CM, Pazzucconi F, Pintó X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001;23(2):177–192.
15. Berkland C, Kim K, Pack DW. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release. 2001;73:59–74.
16. Brazel CS, Peppas NA. Modeling of drug release from swellable polymers. Eur J Pharm Biopharm. 2000;49:47–58.
17. Franssen O, Stenekes RJ, Hennink WE. Controlled release of a model protein from enzymatically degrading dextran microspheres. J Control Release. 1999;59:219–228.
18. Oneda F, Re MI. The effect of formulation variables on the dissolution and physical properties of spray-dried microspheres containing organic salts. Powder Technol. 2003;130:377–384.
19. Araujo L, Sheppard M, Löbenberg R, Kreuter J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int J Pharm. 1999;176:209–224.
20. Hosny KM, Ali SM. Novel controlled release oxypentifylline microspheres; preparation, characterization and in-vivo evaluation. Afr J Pharm Pharmacol. 2012;6(27):2039–2048.